Anti-fibrosis peptide fragment, vaccine as well as preparation method and application of peptide fragment vaccine

By using fibrosis-specific peptide vaccine, the infection risks and side effects in the treatment of fibrosis diseases are solved, effective prevention and treatment of various fibrosis diseases are achieved, and the deposition of collagen fibers is significantly inhibited.

CN118955693AInactive Publication Date: 2024-11-15SICHUAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411031475.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing treatment methods for fibrotic diseases have the risk of infection, high side effects and are difficult to quickly customize. Traditional vaccines have limited applications in fibrotic diseases and lack effective prevention and treatment methods.

Method used

Fibrolysis-specific peptides derived from MAF, FNDC3A or TOP2A proteins are used as vaccine components, and uniformly encapsulated in lipid delivery vectors through microfluidic methods to form anti-fibrosis peptide vaccines for prevention and treatment of multiple fibrotic disease.

Benefits of technology

It significantly inhibits lung, liver and pancreatic fibrosis caused by drugs, reduces collagen fiber deposition, and reduces pathological changes, providing an effective prevention and treatment plan for fibrotic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955693A_ABST
    Figure CN118955693A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to an anti-fibrosis peptide fragment, a vaccine and a preparation method and application of the peptide fragment vaccine. In order to explore that the peptide fragment is used as a peptide fragment vaccine for fibrotic diseases, the invention provides an anti-fibrosis peptide fragment, a vaccine and a preparation method and application of the peptide fragment vaccine. According to the application disclosed by the invention, main histocompatibility compound restrictive peptide fragments from three protein sources of fibrosis-specific MAF, FNDC3A and TOP2A are taken as targets for treating and preventing fibrosis diseases, the three peptide fragments are taken as vaccines, and various fibrosis diseases are remarkably prevented and treated by inhibiting pathological changes and collagenous fiber deposition caused by fibrosis; fibrosis of lung, liver, pancreas and the like is included. The peptide fragment and the peptide fragment vaccine provided by the invention provide candidate schemes for future research on preventive and therapeutic vaccine transformation of fibrotic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to anti-fibrosis peptides, vaccines, and preparation methods and applications of peptide vaccines thereof. Background Art

[0002] Fibrosis can occur in organs such as the lungs, liver, and pancreas, showing features such as fibroblast proliferation and a large amount of extracellular matrix aggregation accompanied by inflammatory damage and tissue structure destruction. That is, normal tissue is damaged and then repaired abnormally, resulting in structural abnormalities (scar formation). The cause of most pulmonary fibrosis patients is unknown (idiopathic). This group of diseases is called idiopathic interstitial pneumonia (IIP), which is a large category of interstitial lung disease. The most common type of disease in IIP with pulmonary fibrosis as the main manifestation is idiopathic pulmonary fibrosis (IPF), a serious interstitial lung disease that can lead to progressive loss of lung function. In addition, liver fibrosis is a pathophysiological process, which refers to the abnormal proliferation of connective tissue in the liver caused by various pathogenic factors. Any liver damage will have a process of liver fibrosis during the process of liver repair and healing. If the damaging factors cannot be removed for a long time, the long-term fibrosis process will develop into cirrhosis. At the same time, pancreatic fibrosis is a persistent and permanent damage to pancreatic tissue and function caused by chronic pancreatitis. The pancreas shows varying degrees of acinar atrophy, pancreatic duct deformation and fibrosis, which are clinically manifested as abdominal pain, diarrhea or steatorrhea, weight loss and malnutrition, which are symptoms of pancreatic insufficiency. In addition, renal fibrosis, myocardial fibrosis, splenic fibrosis, etc. are also common fibrotic diseases.

[0003] Peptide vaccines are a new type of vaccine that uses artificially synthesized short peptides to stimulate the immune system to produce an immune response against a specific pathogen. These peptides are usually immunogenic fragments of pathogenic proteins. Compared with traditional vaccines, peptide vaccines have several advantages: first, since they do not contain the entire pathogen or its derivatives, there is no potential risk of infection; second, the synthesis process of peptide vaccines is relatively simple, and they can be quickly and flexibly customized to deal with different variants; in addition, since only specific peptides are involved, the potential risk of side effects and allergic reactions is low. The research and development of peptide vaccines is in a rapid development stage and is used in the treatment or prevention of various infectious diseases, or major human diseases, including cancer and fibrotic diseases. At present, although there are many studies on the use of peptides as vaccines for the treatment or prevention of fibrotic diseases, exploring more peptides and using them as peptide vaccines for anti-fibrosis has positive significance for clinical medical research. Summary of the invention

[0004] In order to explore more peptides and use them as peptide vaccines for fibrotic diseases, the purpose of this application is to provide new anti-fibrotic peptides, vaccines and preparation methods and applications of peptide vaccines.

[0005] In order to achieve the above application purpose, the technical solution adopted in this application is as follows:

[0006] In a first aspect, the present invention provides an anti-fibrosis peptide segment, which is derived from fibrosis-specific MAF, FNDC3A or TOP2A protein, wherein the peptide segment is MAF 116-124 、FNDC3A 1101-1108 or TOP2A 1118-1125 , whose amino acid sequence is selected from at least one of SEQ ID NOs: 1 to 3.

[0007] Peptide MAF 116-124 , the amino acid sequence is shown in SEQ ID NO: 1: ALISNSHQL.

[0008] Peptide FNDC3A 1101-1108 , the amino acid sequence is shown in SEQ ID NO: 2: TSFRYSSL.

[0009] Peptide TOP2A 1118-1125 , the amino acid sequence is shown in SEQ ID NO: 3: AGPTFNYL.

[0010] In a second aspect, the present invention provides an anti-fibrosis peptide vaccine comprising the above-mentioned peptide and pharmaceutically acceptable auxiliary ingredients.

[0011] Furthermore, the auxiliary component is an immune adjuvant.

[0012] Furthermore, the immune adjuvant is 1V209-Cho-Lip liposome, which is prepared from cholesterol-modified 1V209 molecule 1V209-Cho, lipid components and cholesterol, wherein the structural formula of 1V209-Cho is shown in Formula II;

[0013] Formula II:

[0014] Furthermore, 1V209 is a synthetic small molecule TLR7 agonist, and its structural formula is shown in Formula I.

[0015] Formula I:

[0016] Wherein, the lipid component is at least one of lecithin, hydrogenated lecithin or synthetic phospholipids.

[0017] Preferably, the lipid component is soy lecithin or hydrogenated soy lecithin.

[0018] Most preferably, the lipid component is hydrogenated soy phosphatidylcholine (HSPC).

[0019] The molar ratio of lipid components, cholesterol and 1V209-Cho in the liposome is 60-70:27-37:1-8.

[0020] The preferred ratio of lipid components, cholesterol and 1V209-Cho in the liposome is a molar ratio of 63-68:30-35:2-4.

[0021] The most preferred ratio among the lipid components, cholesterol and 1V209-Cho in the liposome is 65:32:3.

[0022] Furthermore, the mass ratio of the peptide segment to the lipid delivery carrier is 5:2.

[0023] In a third aspect, the present invention provides the use of the above-mentioned peptide segment or peptide segment vaccine in the preparation of a drug for preventing and / or treating fibrotic diseases.

[0024] Furthermore, in the application, the drug is a pharmaceutical preparation that is administered by injection, oral administration, nasal mucosa, lungs, rectum, oral mucosa or skin.

[0025] Furthermore, the drug is an injectable preparation, and the injection route is at least one of intramuscular injection, intravenous injection, subcutaneous injection, intradermal injection, intramyocardial injection or intraperitoneal injection.

[0026] Furthermore, the fibrotic disease includes at least one of pulmonary fibrosis, liver fibrosis, pancreatic fibrosis, renal fibrosis, cardiac fibrosis, endometrial fibrosis, eye fibrosis, splenic fibroproliferative disease, myelofibrosis or skin fibrosis.

[0027] Furthermore, the pulmonary fibrosis includes at least one of idiopathic pulmonary fibrosis, secondary pulmonary fibrosis, hereditary pulmonary fibrosis or other pulmonary fibrosis. Preferably, the pulmonary fibrosis is caused by drugs, and the drugs are at least one of bleomycin, amiodarone or methotrexate.

[0028] Furthermore, the liver fibrosis is liver fibrosis caused by viral hepatitis, alcoholic hepatitis, autoimmune disease, fatty liver, malnutrition, chronic congestive heart failure or drugs, liver fibrosis of other unknown etiology, or diseases induced by liver fibrosis. Preferably, the liver fibrosis is caused by drugs, and the drugs are at least one of carbon tetrachloride or phosphorus.

[0029] Furthermore, the pancreatic fibrosis is a disease induced by acute pancreatitis, chronic pancreatitis, pancreatic duct obstruction, chronic alcoholism, pancreatic ischemia or pancreatic fibrosis. Preferably, the pancreatic fibrosis is induced by a drug, and the drug is caerulein.

[0030] Furthermore, in the application, the drug inhibits pathological changes caused by fibrosis, massive proliferation of fibroblasts and deposition of collagen.

[0031] In a fourth aspect, the present invention provides a combination anti-fibrosis drug, which contains the above-mentioned peptide segment or peptide segment vaccine and other anti-fibrotic disease drugs, which are administered separately or simultaneously.

[0032] In a fifth aspect, the present invention provides a method for preparing the above-mentioned peptide vaccine, which is prepared by mixing the above-mentioned peptide vaccine with pharmaceutically acceptable auxiliary ingredients.

[0033] Furthermore, the preparation method of the above-mentioned peptide vaccine is to uniformly encapsulate the above-mentioned peptide in the lipid delivery carrier 1V209-Cho-Lip liposome by a microfluidic method.

[0034] Furthermore, the mass ratio of the peptide segment to the lipid delivery carrier is 5:2.

[0035] More preferably, the preparation method of the peptide vaccine comprises the following steps:

[0036] The lipid components, cholesterol and 1V209-Cho are mixed in an organic solvent in proportion and used as the organic phase; the peptide aqueous solution is used as the aqueous phase. The organic phase and the aqueous phase are mixed through a microfluidic system, the peptide is encapsulated, and then ultrafiltered to obtain a purified peptide vaccine.

[0037] Among them, the molar ratio between lipid components, cholesterol and 1V209-Cho is 60-70:27-37:1-8.

[0038] The preferred ratio among lipid components, cholesterol and 1V209-Cho in the liposome is a molar ratio of 63-68:30-35:2-4.

[0039] The most preferred ratio among lipid components, cholesterol and 1V209-Cho in liposomes is 65:32:3.

[0040] The volume ratio of the organic phase to the aqueous phase is 1:1-4; preferably, the volume ratio of the organic phase to the aqueous phase is 1:3.

[0041] Among them, the microfluidic operating temperature is 35-37°C.

[0042] Among them, the ultrafiltration time is 20 to 25 minutes, and the rotation speed is 3500 to 4000 rpm.

[0043] Beneficial effects: The present invention uses fibrosis neoantigens as targets and uses the major histocompatibility complex restricted peptide MAF from three fibrosis-specific proteins: MAF, FNDC3A, and TOP2A. 116-124 、FNDC3A1101-1108 or TOP2A 1118-1125 As a target for the treatment and prevention of fibrotic diseases, it is used as a peptide vaccine to prevent and treat a variety of fibrotic diseases. The results of animal experiments show that the peptide vaccine of the present invention can significantly treat drug-induced lung, liver and pancreatic fibrosis with the help of a lipid delivery system. And the purpose of treating fibrotic diseases is achieved by inhibiting the pathological changes caused by fibrosis and the deposition of collagen fibers. Therefore, the peptide vaccine of the present invention provides a better candidate vaccine for future preventive and therapeutic vaccine transformation research on fibrotic diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 The results of the PEP-VAC vaccines with three different protein sources in Example 1 in treating bleomycin-induced pulmonary fibrosis in mice; a) Masson staining of lung tissue pathological sections of mice vaccinated with PEP-VAC with three different protein sources and mice not vaccinated with PEP-VAC in the pulmonary fibrosis treatment model; b) Lung coefficients of mice vaccinated with PEP-VAC with three different protein sources and mice not vaccinated with PEP-VAC in the pulmonary fibrosis treatment model; c) Hydroxyproline content of lung tissue of mice vaccinated with MAF-VAC, FNDC3A-VAC or TOP2A-VAC and mice not vaccinated with PEP-VAC in the pulmonary fibrosis treatment model. Data are expressed as mean ± SEM. Scale bar: 50 μm.

[0045] Figure 2 The results of the PEP-VAC vaccine in Example 2 in treating carbon tetrachloride-induced liver fibrosis in mice; a) Sirius red staining of liver tissue pathological sections in the liver fibrosis treatment model of mice vaccinated with MAF-VAC, FNDC3A-VAC and not vaccinated with PEP-VAC; b) The percentage of Sirius red staining positive areas in the liver fibrosis treatment model of mice vaccinated with MAF-VAC, FNDC3A-VAC and not vaccinated with PEP-VAC; c) The hydroxyproline content of liver tissue in the liver fibrosis treatment model of mice vaccinated with MAF-VAC, FNDC3A-VAC and not vaccinated with PEP-VAC. Data are expressed as mean ± SEM. Scale bar: 50 μm.

[0046] Figure 3 The PEP-VAC vaccine in Example 3 treats pancreatic fibrosis induced by caerulein in mice; a) Masson staining of pancreatic tissue pathological sections of mice vaccinated with MAF-VAC, FNDC3A-VAC and not vaccinated with PEP-VAC in the pancreatic fibrosis treatment model; b) Hydroxyproline content of pancreatic tissue of mice vaccinated with MAF-VAC, FNDC3A-VAC and not vaccinated with PEP-VAC in the pancreatic fibrosis treatment model. Data are expressed as mean ± SEM. Scale bar: 50 μm.

[0047] Figure 4 Peptide MAF 116-124 、FNDC3A 1101-1108 、TOP2A 1118-1125 Structural diagram and structural formula; a) is peptide MAF 116-124 、FNDC3A 1101-1108 、TOP2A 1118-1125 Structure diagram; b) peptide MAF 116-124 、FNDC3A 1101-1108 、TOP2A 1118-1125 The structural formula of . DETAILED DESCRIPTION

[0048] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clear, the present application is further described in detail below in combination with the implementation methods. Unless otherwise defined, all scientific and technological terms used herein have the same meanings as understood by ordinary technicians in the field.

[0049] The present invention uses MAF 116-124 、FNDC3A 1101-1108 、TOP2A 1118-1125 The three peptides are used as targets for treating and preventing fibrotic diseases, and peptide vaccines are prepared using the three peptides for treating and preventing fibrotic diseases.

[0050] In one embodiment of the present invention, a major histocompatibility complex-restricted peptide fragment derived from a fibrosis-specific protein is used, including MAF 116-124 、FNDC3A 1101-1108 、TOP2A 1118-1125 The peptide vaccine PEP-VAC was prepared to treat and prevent various fibrotic diseases. Its therapeutic effect in fibrotic diseases was further explored with the help of lipid delivery system.

[0051] The peptide vaccine described in the present invention is a new type of vaccine that uses artificially synthesized short peptides to stimulate the immune system to produce an immune response against a specific pathogen. These peptides are usually immunogenic fragments of pathogenic proteins. Compared with traditional vaccines, it has several advantages: first, since it does not contain the entire pathogen or its derivatives, there is no potential risk of infection; second, the synthesis process is relatively simple and can be quickly and flexibly customized to cope with different variants; in addition, since only specific peptides are involved, the potential risk of side effects and allergic reactions is low.

[0052] The peptide vaccine of the present invention is prepared by adding pharmaceutically acceptable auxiliary ingredients such as immune adjuvants to the above three peptides. Any drug containing the above peptides and used as an anti-fibrosis drug such as a peptide vaccine and its preparation method falls within the scope of protection of the present invention.

[0053] In a specific embodiment of the present invention, the peptides are used for anti-fibrosis via lipid delivery carriers. More specifically, the three peptides are uniformly encapsulated in lipid delivery carrier 1V209-Cho-Lip liposomes via microfluidics to prepare peptide vaccines for the prevention and treatment of fibrosis.

[0054] The peptide vaccine is obtained by first using an organic mixture of 1V209-Cho, lipid components and cholesterol as an organic phase and a peptide solution as an aqueous phase, using a microfluidic system to uniformly encapsulate the peptide in 1V209-Cho-Lip liposomes, and ultrafiltration purification.

[0055] The lipid component is lecithin, hydrogenated lecithin or synthetic phospholipids, preferably soybean lecithin or hydrogenated soybean lecithin, and most preferably hydrogenated soybean lecithin (HSPC).

[0056] The molar ratio of lipid components, cholesterol and 1V209-Cho in the liposome is 60-70:27-37:1-8. The preferred molar ratio is 63-68:30-35:2-4. The most preferred ratio is 65:32:3.

[0057] Among them, the mass ratio of peptide segment and lipid delivery carrier is 5:2.

[0058] The fibrosis diseases described in the present invention are induced by a variety of factors. After these factors cause tissue damage, during the repair process, collagen, extracellular matrix, and fibronectin produced by myofibroblasts are deposited in the tissue, resulting in tissue structural remodeling and seriously affecting organ function.

[0059] The fibrotic disease of the present invention includes at least one of pulmonary fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, endometrial fibrosis, eye fibrosis, spleen fibrosis, myelofibrosis or skin fibrosis.

[0060] Wherein, pulmonary fibrosis includes at least one of idiopathic pulmonary fibrosis, secondary pulmonary fibrosis, hereditary pulmonary fibrosis or other pulmonary fibrosis. In a preferred embodiment of the present invention, the pulmonary fibrosis is caused by a drug, and the drug is at least one of bleomycin, amiodarone or methotrexate.

[0061] In a specific embodiment of the present invention, tracheal instillation of bleomycin was used to construct a mouse pulmonary fibrosis model, and the results showed that intramuscular injection of PEP-VAC vaccine can effectively treat collagen deposition, increased hydroxyproline content, and pathological changes in lung tissue in mice caused by bleomycin.

[0062] Liver fibrosis refers to the abnormal proliferation of connective tissue in the liver caused by various pathogenic factors. Any liver damage will lead to liver fibrosis in the process of liver repair and healing. If the damaging factors cannot be removed for a long time, the fibrosis process will develop into cirrhosis. Viral hepatitis, alcoholic hepatitis, autoimmune diseases, fatty liver, malnutrition, chronic congestive heart failure or drugs can cause liver fibrosis, and liver fibrosis also includes other liver fibrosis of unknown cause, or diseases induced by liver fibrosis. In a preferred embodiment of the present invention, the liver fibrosis is caused by drugs, and the drugs are at least one of carbon tetrachloride or phosphorus.

[0063] In a specific embodiment of the present invention, intraperitoneal injection of carbon tetrachloride was used to construct a mouse liver fibrosis model, and the results showed that intramuscular injection of PEP-VAC vaccine can effectively treat the pathological changes and collagen deposition in mouse liver tissue caused by carbon tetrachloride.

[0064] Pancreatic fibrosis is a persistent and permanent damage to pancreatic tissue and function caused by various factors. The pancreas shows varying degrees of acinar atrophy, pancreatic duct deformation and fibrosis. Clinically, it mainly manifests as abdominal pain, diarrhea or steatorrhea, weight loss and malnutrition, which are symptoms of pancreatic insufficiency. The pancreatic fibrosis described in the present invention is a disease induced by acute pancreatitis, chronic pancreatitis, pancreatic duct obstruction, chronic alcoholism, pancreatic ischemia or pancreatic fibrosis. In a preferred embodiment of the present invention, the pancreatic fibrosis is caused by a drug, and the drug is caerulein.

[0065] In a specific embodiment of the present invention, intraperitoneal injection of caerulein was used to construct a mouse liver fibrosis model, and the results showed that intramuscular injection of PEP-VAC vaccine can effectively treat the pathological changes and collagen deposition in the pancreatic tissue of mice caused by caerulein.

[0066] Renal fibrosis is renal fibrosis caused by hypertension, glomerulonephritis, systemic lupus erythematosus, scleroderma, renal transplant rejection, pyelonephritis, kidney stones, hyperlipidemia, diabetes, hyperuricemia, hypercalciuria, other causes of unknown renal fibrosis, and diseases induced by renal fibrosis.

[0067] Cardiac fibrosis is cardiac fibrosis, cardiac remodeling and myocardial hypertrophy caused by ischemic heart disease, hypertension, viral myocarditis, metabolic cardiomyopathy, Keshan disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy and arrhythmia, as well as other cardiac fibrosis of unknown causes and diseases induced by cardiac fibrosis.

[0068] Endometrial fibrosis refers to endometrial fibrosis lesions caused by different reasons, such as endometriosis, as well as diseases induced by endometrial fibrosis.

[0069] Ocular fibrosis is a retinal fibroproliferative disease caused by eye trauma, eye surgery and diabetes, as well as diseases induced by ocular fibrosis.

[0070] Myelofibrosis is idiopathic and drug-induced myelofibrosis, polycythemia vera, chronic myeloid leukemia, Hodgkin's disease, and myelofibrosis-induced disorders.

[0071] Specific examples will be listed below to explain the scheme of the present invention. It will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the examples, the techniques or conditions described in the literature in this area or the product instructions are used. Reagents or instruments used that do not indicate manufacturers are all conventional products that can be obtained commercially.

[0072] Peptide MAF 116-124 (amino acid sequence: ALISNSHQL), FNDC3A 1101-1108 (amino acid sequence: TSFRYSSL), TOP2A 1118-1125 (Amino acid sequence: AGPTFNYL) Dry powder was purchased from Gill Biochemical Co., Ltd. 1V209-Cho was prepared by referring to the article Nano Lett. 2021, 21, 7960-7969 or patent CN118217247A from commercially available 1V209 (Selleck); the kit for detecting tissue hydroxyproline content was purchased from Nanjing Jiancheng Bioengineering Institute. Male C57BL / 6 mice (8-10 weeks) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. All animal experiments were performed in accordance with the guidelines evaluated and approved by the Ethics Committee of Sichuan University.

[0073] 1V209-Cho was prepared by the following synthetic means:

[0074] Step a, dissolving cholesterol, EDCI and DMAP in 10 mL DCM at a ratio of 1 eq: 2 eq: 0.1 eq, then adding boc-aminobutyric acid in an amount of 1.2 eq, reacting at room temperature for 24 hours, adding 25 mL DCM, extracting the organic layer, washing with brine, drying over anhydrous sodium sulfate, and concentrating in vacuo to obtain a crude product, which was purified by silica gel chromatography using petroleum ether / ethyl acetate to obtain product 1;

[0075] Product 1:

[0076] Step b, product 1 was dissolved in 5 mL DCM, and 10% TFA was added, stirred at room temperature for 1 h, 25 mL DCM was added, the organic layer was extracted, washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain product 2;

[0077] Product 2:

[0078] Step c, 1V209, HATU and TEA are dissolved in 5 mL DMF in a ratio of 1 eq: 1.2 eq: 2 eq, and then the product 2 dissolved in DMF is added, the amount of product 2 is 1.2 eq, and after reacting at room temperature for 48 hours, the solvent DMF is removed by rotary evaporation to obtain a crude product, which is purified by silica gel chromatography using dichloromethane / methanol to obtain 1V209-Cho.

[0079] Preparation of PEP-VAC vaccine

[0080] The preparation of PEP-VAC vaccines, including: MAF-VAC, FNDC3A-VAC and TOP2A-VAC vaccines, is carried out by a liposome delivery system, using a microfluidic method: the liposome delivery carrier: lipid components HSPC, cholesterol and 1V209-Cho are dissolved in anhydrous ethanol and dimethyl sulfoxide at a molar ratio of 65:32:3 and used as an organic phase (anhydrous ethanol and dimethyl sulfoxide volume ratio is 10:1). The peptide dissolved in physiological saline is used as the aqueous phase, and the mass ratio of the peptide to the prepared liposome delivery carrier is 5:2. The organic phase and the aqueous phase are quickly passed through the microfluidic chip at a volume ratio of 1:3 at 37°C. Finally, the liquid obtained by microfluidic mixing is ultrafiltered at 4000rpm for 20 minutes to remove water, organic solvents and unencapsulated peptides, and finally a purified MAF-VAC vaccine solution is obtained, and the volume of the liposome-encapsulated peptide is adjusted to 1.2mL using physiological saline to complete the preparation of the peptide vaccine. This process is also applicable to FNDC3A-VAC and TOP2A-VAC, just use the corresponding peptide solutions. Through ultrafiltration, it can be ensured that there are only active ingredients in the vaccine solution without unencapsulated peptides or other impurities, thereby improving the purity and stability of the vaccine.

[0081] Example 1 Efficacy of PEP-VAC in treating pulmonary fibrosis in mice

[0082] To investigate the ability of PEP-VAC to treat pulmonary fibrosis in mice, mice were injected intramuscularly with PEP-VAC (50 μg MAF) dissolved in saline on days 0, 7, and 14. 116-124 or FNDC3A 1101-1108 or TOP2A 1118-1125 / mouse, converted to 1.25μg / kg mouse), and 3mg / kg bleomycin was sublingually dripped into each mouse on the first day to establish an in vivo mouse pulmonary fibrosis model. 28 days after the drip of bleomycin, the mice were killed and lung tissues were isolated to evaluate the case characteristics. The results of Masson staining showed that Figure 1 a, In the treatment model, the three PEP-VAC immunization groups of mice had significantly reduced lung collagen fibers after bleomycin treatment. In addition, in the treatment model, the three PEP-VAC immunizations significantly inhibited the increase in lung coefficient (lung weight / body weight) caused by pulmonary fibrosis, among which we found that MAF 116-124 or FNDC3A 1101-1108 The prepared PEP-VAC vaccine has the most significant therapeutic effect on pulmonary fibrosis, such as Figure 1 b. Hydroxyproline is one of the main components of collagen tissue and is an important indicator for evaluating the degree of pulmonary fibrosis. We used a hydroxyproline kit to further analyze the hydroxyproline content in the lungs of mice treated with three types of PEP-VAC. Figure 1 c, The results showed that in the treatment model, all three PEP-VAC vaccines could reduce the content of hydroxyproline in the lungs of mice treated with bleomycin. Based on the above results, in the treatment model, PEP-VAC derived from multiple fibrosis-specific proteins can effectively alleviate bleomycin-induced pulmonary fibrosis in mice and is a potential candidate vaccine for the treatment of idiopathic pulmonary fibrosis.

[0083] Example 2 Efficacy of PEP-VAC in treating liver fibrosis in mice

[0084] MAF 116-124 FNDC3A 1101-1108 The prepared PEP-VAC showed good therapeutic effect in mouse pulmonary fibrosis. In order to further verify the ability of these two peptide vaccines to treat liver fibrosis in mice, mice were injected intramuscularly with PEP-VAC (50 μg MAF 116-124 or FNDC3A 1101-1108 / mice), and starting from the first day, 100 μL of 20% volume concentration of carbon tetrachloride (dissolved in corn oil) was injected into the mouse peritoneum every 3 days to establish a mouse liver fibrosis model. 72 hours after the 12th injection, the mice were killed and the liver tissues were isolated to evaluate the case characteristics. Sirius red staining results showed that Figure 2 a, In the treatment model, receiving MAF 116-124 or FNDC3A 1101-1108 The prepared PEP-VAC vaccine-treated mice had significantly reduced collagen in liver tissue after carbon tetrachloride treatment. In addition, the Sirius red staining results were analyzed using the image analysis software Image J, as shown in Figure 2 b, In the treatment model, MAF 116-124 or FNDC3A 1101-1108 The prepared PEP-VAC vaccine also significantly inhibited the increase of collagen in liver fibrosis tissue induced by carbon tetrachloride. In addition, the analysis of hydroxyproline content in mouse liver tissue using a hydroxyproline kit showed that Figure 2 c, In the treatment model, MAF 116-124 or FNDC3A 1101-1108 The prepared PEP-VAC vaccine significantly reduced the content of hydroxyproline in the liver tissue of mice treated with carbon tetrachloride.

[0085] Example 3 Efficacy of PEP-VAC in treating pancreatic fibrosis in mice

[0086] MAF 116-124 FNDC3A 1101-1108 The prepared PEP-VAC showed good therapeutic effects in mouse pulmonary fibrosis and liver fibrosis models. In order to further verify the ability of these two peptide vaccines to treat pancreatic fibrosis in mice, PEP-VAC (50 μg MAF 116-124 or FFNDC3A 1101-1108 / mouse), and from the first day, the mice were intraperitoneally injected with caerulein at a single injection dose of 50 μg / kg for 4 consecutive weeks, with injections on Mondays, Wednesdays, and Fridays, 6 times a day, and one hour between each injection to establish a mouse pancreatic fibrosis model. 72 hours after the last injection, the mice were killed and the pancreatic tissues were isolated to evaluate the case characteristics. The results of Masson staining showed that Figure 3 a, In the treatment model, receiving MAF 116-124 or FNDC3A 1101-1108 The collagen in liver tissue of mice treated with the prepared PEP-VAC vaccine was significantly reduced after caerulein treatment. In addition, the analysis of the hydroxyproline content in pancreatic tissue of mice using a hydroxyproline kit showed that, Figure 3 b, In the treatment model, MAF 116-124 or FNDC3A1101-1108 The prepared PEP-VAC vaccine significantly reduced the hydroxyproline content in the pancreatic tissue of mice treated with caerulein.

Claims

1. Anti-fibrotic peptides, Features: Derived from fibrosis-specific MAF, FNDC3A or TOP2A protein, the peptide segment is MAF 116-124 、FNDC3A 1101-1108 or TOP2A 1118-1125 , wherein the amino acid sequence is selected from at least one of SEQ ID NOs: 1 to 3.

2. Anti-fibrosis peptide vaccine, Features: Contains the peptide segment according to claim 1 and pharmaceutically acceptable auxiliary ingredients.

3. The anti-fibrotic peptide vaccine according to claim 2, Features: The auxiliary component is an immune adjuvant; further, the immune adjuvant is 1V209-Cho-Lip liposome, which is prepared from cholesterol-modified 1V209 molecule 1V209-Cho, lipid components and cholesterol, wherein the structural formula of 1V209-Cho is shown in Formula II; Formula II:

4. The anti-fibrotic peptide vaccine according to claim 3, Features: 1V209 is a synthetic small molecule TLR7 agonist, and its structural formula is shown in Formula I. Formula I:

5. The anti-fibrotic peptide vaccine according to claim 3 or 4, Features: At least one of the following is met: The lipid component is at least one of lecithin, hydrogenated lecithin or synthetic phospholipids; preferably, the lipid component is soybean lecithin or hydrogenated soybean lecithin; most preferably, the lipid component is HSPC; The molar ratio of lipid components, cholesterol and 1V209-Cho in the liposome is 60-70:27-37:1-8; the preferred molar ratio is 63-68:30-35:2-4; the most preferred ratio is 65:32:3; The mass ratio of the peptide segment to the lipid delivery carrier is 5:

2.

6. Use of the peptide segment according to claim 1 or the peptide segment vaccine according to any one of claims 2 to 5 in the preparation of a drug for preventing and / or treating fibrotic diseases.

7. The use according to claim 6, Features: The drug is a pharmaceutical preparation that is administered by injection, oral administration, nasal mucosa, lungs, rectum, oral mucosa or skin; further, the drug is an injection preparation, and the injection route is at least one of intramuscular injection, intravenous injection, subcutaneous injection, intradermal injection, intramyocardial injection or intraperitoneal injection.

8. The use according to claim 6 or 7, Features: The fibrotic disease includes at least one of pulmonary fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, endometrial fibrosis, eye fibrosis, spleen fibroproliferative disease, myelofibrosis or skin fibrosis.

9. Combination of anti-fibrotic drugs, Features: Contains the peptide segment according to claim 1 or the peptide segment vaccine according to any one of claims 2 to 5, and other anti-fibrotic disease drugs, which are administered separately or simultaneously.

10. A method for preparing the peptide vaccine according to any one of claims 2 to 5, which is prepared by mixing the peptide according to claim 1 with pharmaceutically acceptable auxiliary ingredients; further, the peptide is uniformly encapsulated in the lipid delivery carrier 1V209-Cho-Lip liposome by a microfluidic method.

Citation Information

Cited By

  • Anti-fibrotic peptide, vaccine, preparation method for peptide vaccine, and use thereof

    WO2026026264A1